What is NuSep?
NuSep, originally spun out of Life Therapeutics Ltd in December 2006 and listed on the ASX in May 2007, has evolved significantly. The company's foundational technologies include Gels and SpermSep, transferred during its spin-out. NuSep has since focused on developing its PrIME technology, targeting the therapeutic plasma market, and has also advanced its SpermSep instrument for IVF applications. The company's journey has involved clinical studies demonstrating the efficacy of its technologies, alongside strategic capital raising efforts to support its development pipeline.
How much funding has NuSep raised?
NuSep has raised a total of $14K across 1 funding round:
Debt
$14K
Debt (2021): $14K with participation from PPP
Key Investors in NuSep
PPP
Public-Private Partnership
What's next for NuSep?
With the recent capital infusion, NuSep is poised to accelerate the commercialization of its SpermSep instrument, responding to demands from IVF clinicians. Concurrently, the company continues to focus on its PrIME technology for the therapeutic plasma market. The Series A/B growth stage funding suggests a strategic emphasis on expanding market reach, further research and development, and potentially scaling manufacturing capabilities to meet growing demand. NuSep's ability to leverage its technological advancements in both the therapeutic plasma and reproductive health sectors will be critical for its sustained growth and market penetration.
See full NuSep company page
